Phase 3 DETERMINE Study in Dermatomyositis

Topline results from the study are on track to be reported in the second quarter of 2021.

Study Details:

  • Primary Endpoint: American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis at Week 28, lenabasum taken twice daily vs. placebo‚Äč (n = 176)
  • Key Secondary Endpoints: Definition of Improvement, Investigator Global Assessment scale of skin activity, and Cutaneous Dermatomyositis Activity and Severity Index activity score
  • For Complete Study Details, Please View the Study Listing on Identifier: NCT03813160

Medical professionals may email us at for more information about study participation.

Patients, caregivers or patient advocates looking for additional information may email us at

For any other inquiries, please see our Contact Us page.